Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats

Journal of Hepatology

Volumn 40, Issue 6, 2004, Pages 934-941

  Arumugam, Thiruma V ^a   Woodruff, Trent M ^a   Stocks, Shelli Z ^a   Proctor, Lavinia M ^a   Pollitt, Sandra ^a   Shiels, Ian A ^a   Reid, Robert C ^a   Fairlie, David P ^a   Taylor, Stephen M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

C5a receptor antagonist; Hepatic ischaemia reperfusion; Inflammation; Myeloperoxidase; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; C5A RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; MYELOPEROXIDASE; PHENYLALANYLORNITHYLPROLYL DEXTRO CYCLOHEXYLALANYLTRYPTOPHYLARGININE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; LIVER INJURY; LIVER ISCHEMIA; LIVER PROTECTION; MORTALITY; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; COMPLEMENT C5A; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; RECEPTOR, ANAPHYLATOXIN C5A; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442673832     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(04)00066-2     Document Type: Article

References (46)

1. Bremer C., Bradford B.U., Hunt K.J., Knecht K.T., Connor H.D., Mason R.P., et al. Role of Kupffer cells in the pathogenesis of hepatic reperfusion injury. Am J Physiol. 267:1994;G630-G636
2. Hisama N., Yamaguchi Y., Ishiko T., Miyanari N., Ichiguchi O., Goto M., et al. Kupffer cell production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion injury in rats. Hepatology. 24:1996;1193-1198
3. Henrion J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis. Acta Gastroenterol Belg. 63:2000;336-347
4. Jaeschke H., Bautista A.P., Spolarics Z., Spitzer J.J. Superoxide generation by neutrophils and Kupffer cells during in vivo reperfusion after hepatic ischemia in rats. J Leukoc Biol. 52:1992;377-382
5. Suzuki S., Toledo-Pereyra L.H., Rodriguez F., Lopez F. Role of Kupffer cells in neutrophil activation and infiltration following total hepatic ischemia and reperfusion. Circ Shock. 42:1994;204-209
6. Wanner G.A., Ertel W., Muller P., Hofer Y., Leiderer R., Menger M.D., et al. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock. 5:1996;34-40
7. Jaeschke H., Farhood A., Bautista A.P., Spolarics Z., Spitzer J.J. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol. 264:1993;G801-G809
8. Lehmann T.G., Koeppel T.A., Munch S., Heger M., Kirschfink M., Klar E., et al. Impact of inhibition of complement by sCR1 on hepatic microcirculation after warm ischemia. Microvasc Res. 62:2001;284-292
9. Arumugam T.V., Shiels I.A., Woodruff T.M., Reid R.C., Fairlie D.P., Taylor S.M. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res. 103:2002;260-267
10. Arumugam T.V., Shiels I.A., Strachan A.J., Abbenante G., Fairlie D.P., Taylor S.M. A small molecule antagonist of C5a receptors protects kidneys from ischemia-reperfusion injury in rats. Kidney Int. 63:2003;134-142
11. Heller T., Hennecke M., Baumann U., Gessner J.E., Zu Vilsendorf A.M., Baensch M., et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol. 163:1999;985-994
12. Ivey C.L., Williams F.M., Collins P.D., Jose P.J., Williams T.J. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J Clin Invest. 95:1995;2720-2728
13. Woodruff T.M., Arumugam T.V., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. A potent C5a receptor antagonist inhibits markers of local and remote organ injury following tourniquet-induced limb ischemia-reperfusion in rats. J Surg Res. 116:2004;81-90
14. Damerau B., Grunefeld E., Vogt W. Chemotactic effects of the complement-derived peptides C3a, C3ai and C5a (classical anaphylatoxin) on rabbit and guinea-pig polymorphonuclear leukocytes. Naun Schm Arch Pharmacol. 305:1978;181-184
15. Jagels M.A., Chambers J.D., Arfors K.E., Hugli T.E. C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood. 85:1995;2900-2909
16. Tyagi S., Klickstein L.B., Nicholson-Weller A. C5a-stimulated human neutrophils use a subset of beta2 integrins to support the adhesion-dependent phase of superoxide production. J Leukoc Biol. 68:2000;679-686
17. Mack C., Jungermann K., Gotze O., Schieferdecker H.L. Anaphylatoxin C5a actions in rat liver: synergistic enhancement by C5a of lipopolysaccharide- dependent alpha (2)-macroglobulin gene expression in hepatocytes via IL-6 release from Kupffer cells. J Immunol. 167:2001;3972-3979
18. Lehmann T.G., Heger M., Munch S., Kirschfink M., Klar E. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int. 13:2000;S547-S550
19. Finch A.M., Wong A.K., Paczkowski N.J., Wadi S.K., Craik D.J., Fairlie D.P., et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem. 42:1999;1965-1974
20. Short A., Wong A.K., Finch A.M., Haaima G., Shiels I.A., Fairlie D.P., et al. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol. 126:1999;551-554
21. Strachan A.J., Woodruff T.M., Haaima G., Fairlie D.P., Taylor S.M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol. 164:2000;6560-6565
22. Strachan A.J., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol. 134:2001;1778-1786
23. Woodruff T.M., Strachan A.J., Dryburgh N., Shiels I.A., Reid R.C., Fairlie D.P., et al. Anti-arthritic activity of an orally active C5a receptor antagonist against antigen-induced monoarticular arthritis in the rat. Arthritis Rheum. 46:2002;2476-2485
24. Woodruff T.M., Arumugam T.V., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 171:2003;5514-5520
25. Mizutani A., Okajima K., Uchiba M., Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood. 95:2000;3781-3787
26. Lemasters J.J., Thurman R.G. Reperfusion injury after liver preservation for transplantation. Annu Rev Pharmacol Toxicol. 37:1997;327-338
27. Lentsch A.B., Kato A., Yoshidome H., Mcmasters K.M., Edwards M.J. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology. 32:2000;169-173
28. Liu D.L., Jeppsson B., Hakansson C.H., Odselius R. Multiple-system organ damage resulting from prolonged hepatic inflow interruption. Arch Surg. 131:1996;442-447
29. Fan C., Zwacka R.M., Engelhardt J.F. Therapeutic approaches for ischemia/reperfusion injury in the liver. J Mol Med. 77:1999;577-592
30. Jaeschke H., Bautista A.P., Spolarics Z., Spitzer J.J. Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. Free Radic Res Commun. 15:1991;277-284
31. Zwacka R.M., Zhang Y., Halldorson J., Schlossberg H., Dudus L., Engelhardt J.F. CD4(+) T-lymphocytes mediate ischemia reperfusion-induced inflammatory responses in mouse liver. J Clin Invest. 100:1997;279-289
32. Liu P., Mcguire G.M., Fisher M.A., Farhood A., Smith C.W., Jaeschke H. Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. Shock. 3:1995;56-62
33. Mosher B., Dean R., Harkema J., Remick D., Palma J., Crockett E. Inhibition of Kupffer cells reduced CXC chemokine production and liver injury. J Surg Res. 99:2001;201-210
34. Jaeschke H. Pathophysiology of hepatic ischemia-reperfusion injury: the role of complement activation. Gastroenterology. 107:1994;583-586
35. Jaeschke H., Smith C.W., Clemens M.G., Ganey P.E., Roth R.A. Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol. 139:1996;213-226
36. Farhood A., Mcguire G.M., Manning A.M., Miyasaka M., Smith C.W., Jaeschke H. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol. 57:1995;368-374
37. Amsterdam E.A., Stahl G.L., Pan H.L., Rendig S.V., Fletcher M.P., Longhurst J.C. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 268:1995;H448-H457
38. Van Beek J., Bernaudin M., Petit E., Gasque P., Nouvelot A., Mackenzie E.T., et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol. 161:2000;373-382
39. Straatsburg I.H., Boermeester M.A., Wolbink G.J., Van Gulik T.M., Gouma D.J., Frederiks W.M., et al. Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol. 32:2000;783-791
40. Mastellos D., Papadimitriou J.C., Franchini S., Tsonis P.A., Lambris J.D. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol. 166:2001;2479-2486
41. Strey C.W., Markiewski M., Mastellos D., Tudoran R., Spruce L.A., Greenbaum L.E., et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 198:2003;913-923
42. Gonce M.E., Brackett D.J., Squires R.A., Gibson D.D., Balla A.K., Lerner M.R., et al. Development of circulatory and metabolic shock following transient portal triad occlusion. J Surg Res. 59:1995;534-543
43. Colletti L.M., Remick D.G., Burtch G.D., Kunkel S.L., Strieter R.M., Campbell D.A. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest. 85:1990;1936-1943
44. Witthaut R., Farhood A., Smith C.W., Jaeschke H. Complement and tumor necrosis factor-alpha contribute to Mac-1 (CD11b/CD18) up-regulation and systemic neutrophil activation during endotoxemia in vivo. J Leukoc Biol. 55:1994;105-111
45. Bajt M.L., Farhood A., Jaeschke H. Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am J Physiol. 281:2001;G1188-G1195
46. Lehmann T.G., Koeppel T.A., Kirschfink M., Gebhard M.M., Herfarth C., Otto G., et al. Complement inhibition by soluble complement receptor type 1 improves microcirculation rat liver transplantation. Transplantation. 66:1998;717-722